Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 6.65%
As of Tuesday, July 28, Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 6.65%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. ZNTL
$4.74
-0.18
-3.66%
July 31, 2026 4:00:00 PM
EST
Volume: 941,178
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Commentary & Analysis
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Up 6.35%
As of Monday, July 27, Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 6.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 6.59%
As of Wednesday, July 22, Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 6.59%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Up 5.29%
As of Tuesday, July 21, Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 5.29%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Up 6.26%
As of Monday, July 20, Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 6.26%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ZNTL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $337.4 | $252.6 | 33% |
|
| Shares Out (Mil) | 70.3 | 52.3 | 56% |
|
| Institutional Ownership | 96.2% | 92.1% | 69% |
|
| Float (Mil) | 48.6 | 40.2 | 47% |
|
| Beta | 1.98 | 0.95 | 92% |
|
| Avg Daily Volume (000s) | 1,219 | 455 | 74% |
|
| Price Change (52-week) |
243.5% | 52.9% | 98% |
|
| Growth | ZNTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (3.1%) | (9.9%) | 36% |
|
| EPS (5yr) | 14.6% | 16.0% | 55 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.7% | (15.6%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 6 | 8 | |
| Current EPS | ($0.480) | ($1.668) | ($1.526) | |
| Month Ago EPS | ($0.461) | ($1.736) | ($1.556) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.543) | ($1.770) | ($1.555) | |
| Year/Year Chg | (4.6%) | (12.5%) | (43.9%) | |
| Financials | ZNTL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($124) | ($43) | 9% |
|
| EPS (TTM) | ($1.736) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($126) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $5 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $35 | $5 | 36% |
|
| Enterprise Value (Q1) (Mil) | $94 | $180 | 21% |
|
| Valuation | ZNTL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.84 | 2.56 | 48% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ZNTL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (39.0%) | (49.8%) | 14% |
|
| ROE | (51.9%) | (55.5%) | 15% |
|
| Liabilities to Assets | 27.8% | 30.3% | 19% |
|
| F-Score | 2 | 3 | 7% |
|
Zentalis Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
